|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/22 Nymox Pharmaceutical Corp. 20-F 12/31/21 106:6M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual or Annual-Transition Report by a Foreign HTML 1.05M
Non-Canadian Issuer
4: EX-13.A Annual or Quarterly Report to Security Holders HTML 24K
5: EX-13.B Annual or Quarterly Report to Security Holders HTML 24K
2: EX-12.A Statement re: the Computation of Ratios HTML 29K
3: EX-12.B Statement re: the Computation of Ratios HTML 28K
11: R1 Cover HTML 96K
12: R2 Consolidated Statements of Comprehensive Loss HTML 67K
13: R3 Consolidated Statements of Financial Position HTML 77K
14: R4 Consolidated Statements of Financial Position HTML 26K
(Parenthetical)
15: R5 Consolidated Statements of Cash Flow HTML 76K
16: R6 Consolidated Statements of Changes in Equity HTML 51K
17: R7 Business Activities and Basis of Presentation HTML 31K
18: R8 Going Concern Considerations HTML 28K
19: R9 Significant Estimates HTML 26K
20: R10 Significant Accounting Policies HTML 66K
21: R11 New Accounting Standards and Interpretations HTML 32K
22: R12 Property and Equipment HTML 79K
23: R13 Intangible Assets HTML 26K
24: R14 Accounts Payable and Accrued Liabilities HTML 37K
25: R15 Operating Leases and Commitments HTML 58K
26: R16 Share Capital HTML 39K
27: R17 Stock Options HTML 61K
28: R18 Share Based Compensation HTML 34K
29: R19 Warrants HTML 53K
30: R20 Income Taxes HTML 69K
31: R21 Earnings Per Share HTML 33K
32: R22 Financial Instruments Fair Value Disclosures HTML 27K
33: R23 Finance Income and Finance Costs HTML 39K
34: R24 Segment Disclosures HTML 39K
35: R25 Concentrations HTML 32K
36: R26 Related Party Transactions HTML 37K
37: R27 Research and Development Expenses HTML 37K
38: R28 Personnel Expenses HTML 36K
39: R29 Capital Disclosures and Financial Risk HTML 27K
40: R30 Foreign Exchange Risk HTML 27K
41: R31 Credit Risk HTML 27K
42: R32 Interest Rate Risk HTML 27K
43: R33 Liquidity Risk HTML 33K
44: R34 Subsequent Events HTML 29K
45: R35 Significant Accounting Policies (Policies) HTML 94K
46: R36 Significant Accounting Policies (Tables) HTML 27K
47: R37 New Accounting Standards and Interpretations HTML 29K
(Tables)
48: R38 Property and Equipment (Tables) HTML 77K
49: R39 Accounts Payable and Accrued Liabilities (Tables) HTML 35K
50: R40 Operating Leases and Commitments (Tables) HTML 54K
51: R41 Share Capital (Tables) HTML 35K
52: R42 Stock Options (Tables) HTML 60K
53: R43 Share Based Compensation (Tables) HTML 31K
54: R44 Warrants (Tables) HTML 50K
55: R45 Income Taxes (Tables) HTML 68K
56: R46 Earnings Per Share (Tables) HTML 32K
57: R47 Finance Income and Finance Costs (Tables) HTML 37K
58: R48 Segment Disclosures (Tables) HTML 37K
59: R49 Concentrations (Tables) HTML 30K
60: R50 Related Party Transactions (Tables) HTML 32K
61: R51 Research and Development Expenses (Tables) HTML 35K
62: R52 Personnel Expenses (Tables) HTML 33K
63: R53 Liquidity Risk (Tables) HTML 30K
64: R54 Significant Accounting Policies (Details) HTML 32K
65: R55 Significant Accounting Policies (Details HTML 30K
Narrative)
66: R56 Property and Equipment (Details) HTML 54K
67: R57 Property and Equipment (Details Narrative) HTML 27K
68: R58 Intangible Assets (Details Narrative) HTML 30K
69: R59 Accounts Payable and Accrued Liabilities (Details) HTML 32K
70: R60 Interest Rate Risk (Details Narrative) HTML 25K
71: R61 Credit Risk (Details Narrative) HTML 25K
72: R62 Foreign Exchange Risk (Details Narrative) HTML 25K
73: R63 Capital Disclosures and Financial Risk (Details HTML 36K
Narrative)
74: R64 Operating Leases and Commitment (Details) HTML 31K
75: R65 Operating Leases and Commitment (Details 1) HTML 35K
76: R66 Operating Leases and Commitment (Details HTML 41K
Narrative)
77: R67 Operating leases and other commitment (Details HTML 34K
Narrative)
78: R68 Share Capital (Details) HTML 38K
79: R69 Share capital (Details Narrative) HTML 36K
80: R70 Stock Options (Details) HTML 49K
81: R71 Stock Options (Details 1) HTML 43K
82: R72 Stock Options (Details Narrative) HTML 28K
83: R73 Share Based Compensation (Details) HTML 33K
84: R74 Share Based Compensation (Details Narrative) HTML 40K
85: R75 Warrants (Details) HTML 35K
86: R76 Warrants (Details Narrative) HTML 33K
87: R77 Income Taxes (Details) HTML 37K
88: R78 Income Taxes (Details 1) HTML 28K
89: R79 Income Taxes (Details 2) HTML 83K
90: R80 Income Taxes (Details Narrative) HTML 26K
91: R81 Earnings Per Share (Details) HTML 28K
92: R82 Finance Income and Finance Costs (Details) HTML 39K
93: R83 Segment Disclosures (Details) HTML 40K
94: R84 Concentrations (Details) HTML 35K
95: R85 Related Party Transactions (Details) HTML 34K
96: R86 Related Party Transactions (Details Narrative) HTML 36K
97: R87 Research and Development Expenses (Details) HTML 38K
98: R88 Personnel Expenses (Details) HTML 32K
99: R89 Personnel Expenses (Details Narrative) HTML 30K
100: R90 Liquidity Risk (Details) HTML 33K
101: R91 Subsequent Events (Details Narrative) HTML 46K
104: XML IDEA XML File -- Filing Summary XML 193K
102: XML XBRL Instance -- nymox_20f_htm XML 1.53M
103: EXCEL IDEA Workbook of Financial Reports XLSX 111K
8: EX-101.CAL XBRL Calculations -- nymox-20211231_cal XML 149K
10: EX-101.DEF XBRL Definitions -- nymox-20211231_def XML 439K
7: EX-101.LAB XBRL Labels -- nymox-20211231_lab XML 853K
9: EX-101.PRE XBRL Presentations -- nymox-20211231_pre XML 714K
6: EX-101.SCH XBRL Schema -- nymox-20211231 XSD 308K
105: JSON XBRL Instance as JSON Data -- MetaLinks 280± 340K
106: ZIP XBRL Zipped Folder -- 0001640334-22-000622-xbrl Zip 207K
 | Download this zipped .zip folder |
| Files: | nymox-20211231.xsd nymox-20211231_cal.xml nymox-20211231_def.xml nymox-20211231_lab.xml nymox-20211231_pre.xml nymox_20f.htm nymox_ex12a.htm nymox_ex12b.htm nymox_ex13a.htm nymox_ex13b.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/16 Nymox Pharmaceutical Corp. 20-F 12/31/15 8:1.2M e3 Fil… Computershare/FA 6/03/11 Nymox Pharmaceutical Corp. 20-F/A 12/31/10 7:474K e3 Fil… Computershare/FA 6/30/04 Nymox Pharmaceutical Corp. 20-F 12/31/03 7:1.1M Foley & Lardner/FA 6/27/02 Nymox Pharmaceutical Corp. 20-F 12/31/01 2:246K Foley & Lardner/FA |